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https://doi.org/10.1016/j.stemcr.2019.09.006SUMMARYPrimary tauopathies are characterized neuropathologically by inclusions containing abnormal forms of the microtubule-associated pro-
tein tau (MAPT) and clinically by diverse neuropsychiatric, cognitive, and motor impairments. Autosomal dominant mutations in the
MAPT gene cause heterogeneous forms of frontotemporal lobar degeneration with tauopathy (FTLD-Tau). Common and rare variants
in theMAPT gene increase the risk for sporadic FTLD-Tau, including progressive supranuclear palsy (PSP) and corticobasal degeneration
(CBD).We generated a collection of fibroblasts from 140MAPTmutation/risk variant carriers, PSP, CBD, and cognitively normal controls;
31 induced pluripotent stem cell (iPSC) lines fromMAPTmutation carriers, non-carrier family members, and autopsy-confirmed PSP pa-
tients; 33 genome engineered iPSCs that were corrected or mutagenized; and forebrain neural progenitor cells (NPCs). Here, we present a
resource of fibroblasts, iPSCs, andNPCswith comprehensive clinical histories that can be accessed by the scientific community for disease
modeling and development of novel therapeutics for tauopathies.INTRODUCTION
Frontotemporal lobar degeneration (FTLD) with inclusions
containing the microtubule-associated protein tau (FTLD-
Tau) account for half of all cases of FTLD. This heteroge-
neous group of diseases includes progressive supranuclear
palsy (PSP), corticobasal degeneration (CBD), Pick disease,
and other rare forms of tauopathy. Patients with FTLD-Tau
exhibit a broad range of neurological deficits including
movement and motor neuron disease (e.g., gait and bal-
ance disturbances, impaired speech and swallowing, visual
impairment), psychiatric impairment (e.g., mood and
behavior), and cognitive impairment (e.g., memory, exec-Stem Cell Repor
This is an open access article under the Cutive dysfunction, language and attention) (Perry et al.,
2017). Due to significant overlap in the clinical syndromes,
a definitive diagnosis can only be obtained by postmortem
examination of brain tissue obtained at autopsy or more
rarely by biopsy (Perry et al., 2017). Thus, to understand
disease etiology, it is particularly valuable to generate a
collection of induced pluripotent stem cells (iPSCs) from
patients who have been followed clinically and from
whom detailed neurological, neuroimaging, and neuro-
pathological data and tissues are available. This requires a
coordinated multidisciplinary effort and is the central
impetus for the development of the resource described
here.ts j Vol. 13 j 939–955 j November 12, 2019 j ª 2019 The Author(s). 939
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Neuropathology in FTLD-Tau Associated with MAPT Mutations
Mutation Clinical
Neuropathology Tau
Isoforms Referencesa iPSCs ReportedMacroscopy Microscopy Tauopathy
P301L bvFTD,
personality
change,
language
abnormalities
atrophy of frontal
and temporal lobes,
basal ganglia,
hippocampus, and
depigmentation
of substantia nigra
neuronal loss,
ballooned
neurons,
and gliosis
neurons: tau-
immunoreactive
perinuclear, ring-
like and dot-like
cytoplasmic
inclusions, fibrillary
neuronal inclusions,
and neuropil threads
4R Mirra
et al., 1999
Iovino et al., 2015;
Paonessa et al.,
2019; Silva et al.,
2019
astrocytes: thorn-
shaped inclusions
oligodendrocytes:
coiled bodies
S305I bvFTD,
personality
change,
language
abnormalities,
Parkinsonism
atrophy of medial
temporal lobe,
temporal pole, and
hippocampus
neuronal loss,
gliosis, and
ballooned
neurons
neurons: tau-
immunoreactive
fibrillary inclusions
and diffuse
cytoplasmic staining
4R Kovacs
et al., 2008
N/A
astrocytes: thorn-
shaped inclusions
oligodendrocytes:
coiled bodies
argyrophilic grains
S305N bvFTD,
personality
change,
memory loss
atrophy of frontal
and temporal lobes
neuronal loss
and gliosis
neurons: tau-
immunoreactive Pick
body-like and ring-
like inclusions
4R Boeve et al.,
2005; Iijima
et al., 1999
N/A
astrocytes: thorn-
shaped inclusions
oligodendrocytes:
coiled bodies
S305S bvFTD, memory
loss
atrophy of frontal
and temporal lobes
neuronal loss,
gliosis, and
ballooned
neurons
neurons: tau-
immunoreactive
neurofibrillary tangles
and pretangles
4R Skoglund et al.,
2008; Stanford
et al., 2000
N/A
astrocytes: tuft-
shaped inclusions
oligodendrocytes:
coiled bodies
IVS10+16 bvFTD,
personality
change,
executive
dysfunction,
memory loss,
parkinsonism,
non-fluent
aphasia
atrophy of frontal
and temporal lobes,
cingulate and insular
cortex, hippocampus,
striatum, amygdala
and brainstem
neuronal loss,
gliosis, and
ballooned
neurons
neurons: tau-
immunoreactive
fibrillary inclusions
and diffuse
cytoplasmic staining
4R Janssen et al.,
2002; Lantos
et al., 2002
Espuny-Camacho
et al., 2017;
Esteras et al., 2017;
Paonessa et al.,
2019; Sposito et al.,
2015
astrocytes: thorn-
shaped inclusions
oligodendrocytes:
coiled bodies
(Continued on next page)
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Table 1. Continued
Mutation Clinical
Neuropathology Tau
Isoforms Referencesa iPSCs ReportedMacroscopy Microscopy Tauopathy
V337M antisocial
behavior,
paranoia,
executive
dysfunction
atrophy of frontal
and temporal lobes
and hippocampus
neuronal loss
and gliosis
neurons: tau-
immunoreactive
neurofibrillary
tangles, pretangles,
and neuropil threads
3R & 4R Spillantini et al.,
1996; Spina
et al., 2017
Ehrlich et al., 2015;
Sohn et al., 2019
astrocytes: tuft-
shaped inclusions
oligodendrocytes:
none
G389R progressive
aphasia,
apathy,
rigidity
atrophy of frontal
and temporal lobes,
hippocampus, and
amygdala
neuronal loss
and gliosis
neurons: tau-
immunoreactive
Pick body-like and
filamentous inclusions
3R & 4R Murrell
et al., 1999
N/A
astrocytes: none
oligodendrocytes:
none
R406W memory loss severe atrophy of
frontal and temporal
lobes and
hippocampus
neuronal loss,
gliosis, and
ballooned
neurons
neurons: tau-
immunoreactive
neurofibrillary
tangles, Pick body-
like inclusions
3R & 4R Miyasaka
et al., 2001;
Reed et al., 1997
Imamura et al.,
2016; Jiang
et al., 2018
astrocytes: thorn-
shaped inclusions
oligodendrocytes:
coiled bodies
R406W/
R406W
bvFTD N/A N/A N/A 3R & 4R Behnam
et al., 2015;
Ng et al., 2015
N/A
N/A, not available.
aSee additional references at the AD/FTD Mutation Database (Cruts et al., 2012).While the majority of patients with primary tauopathy
are sporadic, autosomal dominant FTLD-Tau families
have been reported to carry mutations in the microtu-
bule-associated protein tau (MAPT) gene. More than 50
MAPT mutations are reported to cause FTLD-Tau (Table 1;
http://www.molgen.ua.ac.be/ADMutations/) (Cruts et al.,
2012). TheMAPT gene is alternatively spliced in the central
nervous system (CNS) to produce six tau isoforms that
differ based on the presence of the N-terminal insertion
(0N, 1N, 2N) and the number of microtubule-binding re-
peats (MTBR; 3R, 4R; Figure 1). In normal adult human
brains, the ratio of 3R/4R tau is 1:1 (Trabzuni et al., 2012).
MAPT mutation carriers may bear 3-repeat (3R), 4-repeat
(4R), or mixed 3R/4R tau inclusions (Table 1) (Cairns
et al., 2007).
Several mechanisms have been proposed to explain
how MAPT mutations cause disease: abnormal MAPTsplicing, altered microtubule-binding kinetics, impaired
degradation, or tau accumulation and aggregation,
among others (van Swieten and Spillantini, 2007). We
have focused our collection on mutations that represent
these proposed mechanisms. A subset ofMAPTmutations
occur at sites that alter MAPT splicing, resulting in
increased levels of exon 10-containing (4R) mRNA (e.g.,
IVS10+16, S305I, S305N, S305S) (Liu and Gong, 2008).
In the case of intronic mutations such as IVS10+16, no
mutant protein is produced. Instead, there is a shift in
the levels of 4R tau, skewing the normally balanced 3R/
4R tau ratio in human adult brain. Another set of muta-
tions occurs in exon 10, which is exclusively present in
4R tau isoforms (e.g., P301L, P301S) (Hutton et al.,
1998). Many of the mutations located in and around
exon 10 have been implicated in disrupting microtu-
bule-binding kinetics (Dayanandan et al., 1999; FischerStem Cell Reports j Vol. 13 j 939–955 j November 12, 2019 941
Figure 1. MAPT Mutations Cause Primary Tauopathy
(A) Schematic of the location of MAPT mutations reported in this collection. MAPT A152T, V337M, G389R, and R406W occur in all tau
isoforms expressed in the brain. MAPT P301L, P301S, and S305I/N/S occur exclusively in transcripts containing exon 10 (2N4R, 1N4R, and
0N4R). MAPT P301L/S, S305I/N/S and IVS10+16 alter splicing of tau such that more 4R-containing transcripts are expressed.
(B–I) Neuropathology in human brains with primary tauopathies. (B–E)MAPT R406W carrier. (B) Atrophy of the frontal lobe with dilatation
of the lateral ventricle and prominent shrinkage of the medial temporal lobe. Scale bar, 0.5 cm. (C) Neuronal loss, gliosis, and micro-
vacuolation of superficial laminae of the superior temporal gyrus. H&E. (D) Neuronal cytoplasmic PHF1-immunoreactive inclusions are seen
in the hippocampal CA1 subfield. (E) Pick body-like, PHF1-immunoreactive inclusion bodies in the dentate fascia. Scale bar in (C), (D), and
(E), 50 mm. (F and G) Anterior cingulate gyrus of a MAPT V337M carrier. (F) RD4-immunoreactive cytoplasmic inclusions in spindle, also
called von Economo, neurons and surrounding layer V neurons. (G) R3 (RD3) tau-immunoreactive cytoplasmic inclusions in spindle and
surrounding layer V neurons, and in the neuropil. (H) Dentate gyrus of MAPT P301L case showing typical pTAU (CP13) ring-like perinuclear
deposit and Pick body-like inclusions. (I) PSP associated with a MAPT A152T variant. Tufted astrocyte (left; white arrow), neurofibrillary
tangle (center; open arrow), and oligodendroglial coiled bodies (right; black arrow), stained with a phospho-tau antibody (CP13). Scale
bar, 25 mm.et al., 2007). Other MAPT mutations are located some
distance from exon 10 and are expressed by allMAPT tran-
scripts (e.g., R5H, V337M, G389R, R406W); thus, their
mode of action may be linked to aspects of tau biology
beyond microtubule binding, such as membrane associa-
tion (Gauthier-Kemper et al., 2011). Additionally, all
MAPT mutations increase the propensity for the tau
protein to aggregate. Despite the clear association of
MAPT mutations with FTLD-Tau, we have little under-942 Stem Cell Reports j Vol. 13 j 939–955 j November 12, 2019standing of the mechanisms by which these mutations
lead to disease.
Rare and common variants inMAPThave been associated
with increased risk for PSP, CBD, and frontotemporal
dementia (FTD) (Coppola et al., 2012; Ho¨glinger et al.,
2011). MAPT A152T decreases binding of tau to microtu-
bules and increases tau oligomer formation in vitro
(Coppola et al., 2012). When expressed in Caenorhabditis
elegans, MAPT A152T induces neuronal dysfunction,
mislocalization of pre-synaptic proteins, and distorted
mitochondrial distribution and trafficking, and reduces
life span independently of protein aggregation (Butler
et al., 2019; Pir et al., 2016). Mouse models expressing
A152T demonstrate age-dependent neuronal loss and sei-
zures, which occur both in the presence (Decker et al.,
2016) or absence of tau aggregates (Maeda et al., 2016).
iPSC-derived neurons from MAPT A152T carriers exhibit
increased total tau levels and phosphorylation, detergent-
insoluble tau, dysregulation of proteostasis pathways
involving autophagy and lysosomal activity, and vulnera-
bility to specific cellular stressors (Biswas et al., 2016;
Fong et al., 2013; Silva et al., 2016). Our fibroblast and
stem cell resource containing MAPT variants that are pre-
dicted tomodify PSP andCBD risk will allow for the cellular
and molecular dissection of disease phenotypes.
Patient-derived iPSCs have emerged as a powerful
resource to study the molecular mechanisms underlying
neurodegenerative diseases. These iPSCs can be differenti-
ated into the neuronal and glial subtypes that are affected
in primary tauopathies, giving us a tool toward under-
standing the biology of tau in a human cell model that
may more faithfully reflect the endogenous condition. To
date, iPSCs carrying the MAPT mutations N279K, P301L,
V337M, R406W, and IVS10+16 and the risk variant
A152T have been described, and their neural derivatives
show phenotypes such as tau accumulation, tau hyper-
phosphorylation, tau insolubility, vulnerability to specific
cellular stressors, and other phenotypes that begin to reveal
possible disease mechanisms (Ehrlich et al., 2015; Hall-
mann et al., 2017; Imamura et al., 2016; Iovino et al.,
2015; Jiang et al., 2018; Seo et al., 2017; Silva et al., 2016;
Sposito et al., 2015; Wren et al., 2015). Most prior studies,
however, have not included genome-edited isogenic
controls, which increase the power to detect variant-spe-
cific phenotypes by decreasing inter-individual variability.
These promising findings warrant the investment in
a comprehensive, isogenically controlled collection of
MAPT iPSC lines.
Here, we present a resource of fibroblast and iPSC lines
that includes known disease-associated MAPT mutations
and paired isogenic iPSCs, MAPT risk variant carriers, and
PSP-syndrome (PSP-S) and corticobasal syndrome (CBS)
lines from individuals where a MAPT mutation has not
been detected. Most of the cell lines presented in this study
were obtained from participants who underwent detailed
clinical phenotyping, and for whom fluid biomarkers,
imaging biomarkers, and genetic and neuropathological
information are available that can be used for correlative
analyses with cellular phenotypes. Together, this repre-
sents a comprehensive resource that can be accessed
for tauopathy modeling and the discovery of novel
therapeutics.RESULTS
Selection of Fibroblast Lines
Dermal fibroblasts were collected from: (1) families with
pathogenic MAPT mutations; (2) individuals carrying
MAPT missense variants that increase risk for PSP, CBD,
and FTD; (3) sporadic PSP-S and CBS cases; and (4) cogni-
tively normal (non-mutant) controls at the Memory and
Aging Center at the University of California San Francisco,
the Knight Alzheimer Disease Research Center at Washing-
ton University, and the National Institute of Neurological
Disease and Stroke (NINDS) Cell Repository. A total of 36
fibroblast lines were generated from individuals with path-
ogenicMAPTmutations (P301L, S305I, IVS10+16, V337M,
G389R, R406W; Figure 1 and Table 2). These mutations are
representative of some of the most common MAPT muta-
tions and capture the range of clinical and neuropatholog-
ical phenotypes associated with FTLD-Tau (Tables 1 and 2).
The collection also includes fibroblasts from eight MAPT
A152T risk variant carriers, which has been reported to in-
crease the risk for PSP, CBD, and FTD (Coppola et al., 2012).
Additionally, we have banked fibroblast lines from research
participants clinically diagnosed with PSP-S, CBS, or mixed
dementias (Alzheimer’s disease and Lewy body disease)
and from cognitively normal controls (Table 2). These
fibroblasts were obtained from subjects who are part of
larger clinical programs that obtain a detailed clinical his-
tory, including physical and neurological examinations,
cognitive testing, and neuroimaging (magnetic resonance
imaging [MRI], b-amyloid positron emission tomography
[PET], and tau PET). Many fibroblast lines also have corre-
sponding plasma and cerebrospinal fluid (CSF) samples.
Additional covariates for the fibroblast lines including
age at biopsy, sex, and genotypic data are available upon
request from http://neuralsci.org/tau.
The patient-specific fibroblasts in this collection capture
classical aspects of clinical and neuropathology associated
with primary tauopathies (Table 1). AMAPT R406W carrier
presented with progressive memory loss and later devel-
oped the behavioral variant of FTD (bvFTD). Macroscopi-
cally, there was pronounced atrophy of the temporal lobe
(cell line F11362; Figures 1B–1E). Microscopically, there
was severe neuronal loss and gliosis and cortical neurofi-
brillary tangles similar to those seen in Alzheimer’s disease.
Frequent Pick body-like, tau-immunoreactive inclusions
were seen in affected areas including the hippocampus
and dentate gyrus. Tau-immunoreactive glial inclusions
were also present. A MAPT V337M carrier included in
the collection exhibited bvFTD; neuropathological
examination revealed inclusions containing both 3R and
4R tau (cell line GIH6; Figures 1F and 1G). MAPT P301L
cases more commonly present clinically with bvFTD, andStem Cell Reports j Vol. 13 j 939–955 j November 12, 2019 943
Table 2. Dermal Fibroblast Bank to Model Primary Tauopathies
MAPT Classification Clinical Presentation Tau Isoform Mean AAOa Mean Disease Durationa Fibroblasts Families
A152T PSP, CBD, FTLD-Tau bvFTD 4R 57.5 N/A 8 N/A
P301L FTLD-Tau bvFTD 4R 52.6 6.7 13 3
S305I FTLD-Tau/AGD bvFTD 4R 39 2 2 1
IVS10+16 FTLD-Tau bvFTD/AD 4R 49.1 10.3 4 1
V337M FTLD-Tau bvFTD 3R & 4R 51.5 15.4 4 2
G389R FTLD-Tau bvFTD 3R & 4R 39.8 2.5 3 1
R406W FTLD-Tau AD 3R & 4R 56.3 11.5 9 2
R406W/R406W FTLD-Tau bvFTD 3R & 4R 34 7 1 1
WT PSP PSP-S 4R N/A N/A 12 N/A
WT CBD CBS 4R N/A N/A 5 N/A
WT PSP/CBD mixed PSP-S/CBS/mixed 4R N/A N/A 10 N/A
WT normal N/A N/A N/A N/A 69 N/A
AAO, age at onset; bvFTD, behavioral variant frontotemporal dementia; AGD, argyrophilic grain disease; AD, Alzheimer’s disease; PSP, progressive
supranuclear palsy; CBD, cortical basal degeneration; N/A, not available.
aData from the AD/FTD Mutation Database presented in years (Cruts et al., 2012).pathologically display neuronal cytoplasmic inclusions
with perinuclear ring-like concentration and the presence
of mini Pick body-like inclusions (Figure 1H). A MAPT
A152T carrier (cell line FTD19; Figure 1I) included in the
collection presented with symptoms characteristic of
PSP-S, includingmotor slowing, falls, and cervical dystonia
that progressed to dysarthria as well as supranuclear gaze
palsy, and neuropathological examination revealed clas-
sical PSP neuropathology featuring 4R tau-immunoreactive
tufted astrocytes (white arrow in Figure 1I), neurofibrillary
tangles (open arrow in Figure 1I), and oligodendroglial
coiled bodies (black arrow in Figure 1I).
Generation and Characterization of iPSCs
To establish cellular models that can inform on the patho-
physiological mechanisms of MAPT mutations, MAPT risk
variants, and sporadic PSP, including cell types affected
by disease, we reprogrammed a subset of fibroblasts
described in Table 2 into iPSCs. All iPSCswere generated us-
ing non-integrating Sendai virus carrying SOX2, OCT4,
KLF4, and cMYC (Table 3, Figure 2A). Multiple clones are
available for each line. iPSCs were grown in feeder-free
conditions using Matrigel and maintained in mTeSR1.
Resulting iPSCs have been characterized for pluripotency
based on morphology and gene expression markers (Fig-
ures 2B and 2C). We confirmed the silencing of exogenous
Sendai virus-driven pluripotent markers by qPCR (Fig-
ure 2C). Correct mutation propagation was verified by
Sanger sequencing (Figure 2D), chromosomal stability944 Stem Cell Reports j Vol. 13 j 939–955 j November 12, 2019was assessed by karyotyping (Figure 2E), and the capacity
to form cell types from the three germ layers was also
confirmed (Figures 2F and 2G). All iPSC lines reported in
this study meet these quality-control criteria (Table S1
and Figure S1), are included in the cell bank, and are avail-
able upon request from http://neuralsci.org/tau.
Genome Editing and Characterization of iPSCs
Genetic background of individual donors is a large contrib-
utor to phenotypic variability in iPSCs (Kilpinen et al.,
2017). To define phenotypes driven specifically by amutant
or risk allele, we usedCRISPR/Cas9 genome editing to estab-
lish isogenic controls of donor iPSC lines (Figure 2A). For
each set of edited lines, additional iPSC clones were selected
that underwent the CRISPR/Cas9 editing pipeline but
remained unmodified. These unmodified iPSC clones serve
as important controls, in addition to the parental donor
line, to account for selective pressures that may occur dur-
ing the editing process (Budde et al., 2017). Donor iPSC
lines carrying the MAPT mutations IVS10+16, P301L,
S305I, R406W, and V337M have been corrected to wild
type (WT; Tables 4 and S2).
The most commonly used mouse model of tauopathy
overexpressesMAPT P301S (Yoshiyama et al., 2007). Clini-
cally, MAPT P301S carriers present with a more aggressive
form of FTD thanMAPT P301L carriers and have an earlier
age at onset (P301S: mean age at onset 33.7 years andmean
disease duration 4.2 years; P301L: mean age at onset 52.6
years and mean disease duration 6.7 years) (Cruts et al.,
Table 3. Human iPSCs for Modeling Primary Tauopathies
Donor ID
Alternative
Donor ID Mutation
Clinical
Statusa Autopsy Corrected Line Fibroblast Source
Neural
Induction
FTD30 (FTD-FF) 151209SBA1 A152T/WT S pending no UCSF yes
FTD19 (FTD-T) 151209SBA2 A152T/WT S PSP no UCSF yes
GIH2 151209SBA3 A152T/WT A N/A no UCSF yes
FTD38 151209SBA4 A152T/WT A N/A no UCSF yes
GIH169 160311SBA5 A152T/WT S N/A no UCSF yes
GIH56 160311SBA6 A152T/WT S N/A no UCSF yes
TAU6 (Tau1225-7) 160311SBA7 A152T/WT S CBD no UCSF yes
F0510 F0510 P301L/WT A N/A yes NINDS repository yes
F13535 F13535 P301L/WT A N/A no WUSM N/A
F14537 F14537 P301L/WT S FTLD-Tau no WUSM N/A
F14536 F14536 WT/WTb A N/A no WUSM N/A
MHF110 17524NCE1 S305I/WT S N/A no UCSF N/A
75.11 AG255075 S305I/WT N/A N/A yes ARTFL/LEFFTDS N/A
300.12 AG251300 S305N/WT N/A N/A no ARTFL/LEFFTDS N/A
GP1.1 GP-1i S305S/WT N/A FTLD-Tau yes NSWBB N/A
GIH36 160311SBC1 IVS10+16/WT A N/A yes UCSF yes
GIH161 I18XXYYNCG1 WT/WTb A N/A no UCSF N/A
GIH178 I18XXYYNCC3 IVS10+16/WT N/A N/A no UCSF N/A
GIH6 160311SBB1 V337M/WT S FTLD-Tau yes UCSF yes
GIH7 160311SBB2 V337M/WT A N/A yes UCSF yes
GIH155 160311SBB3 V337M/WT S N/A no UCSF N/A
ND32951A ND32951A V337M/WT A N/A yes NINDS repository yes
MHF100 171018NCD1 G389R/WT A N/A no UCSF N/A
MHF101 171018NCD2 G389R/WT A N/A no UCSF N/A
MHF102 171018NCD3 G389R/WT S N/A no UCSF N/A
F11374 F11374 R406W/WT A N/A no WUSM N/A
F11362 F11362 R406W/WT S FTLD-Tau yes WUSM yes
F11421 F11421 R406W/WT A N/A yes WUSM yes
GIH143 UCSF1 R406W/R406W S N/A no UCSF N/A
GIH131 170524NCF1 WT/WT S PSP no UCSF N/A
GIH92 171013NCF3 WT/WT S PSP no UCSF N/A
UCSF, University of California San Francisco Memory and Aging Center; WUSM, Washington University, Knight Alzheimer’s Disease Research Center; NINDS
repository, National Institute of Neurologic Disorders and Stroke; ARTFL/LEFFTDS, Advancing Resource and Treatment for Frontotemporal Dementia/
Longitudinal Evaluations of Familial Frontotemporal Dementia Subjects; NSWBB, New South Wales Brain Bank; N/A, not available.
aAt biopsy: A, asymptomatic; S, symptomatic.
bNon-carrier, related to MAPT family.
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Figure 2. Generation and Characterization of iPSC Models of Tauopathy
Representative images of control (MAPT WT/WT), mutant (MAPT P301L/WT), and CRISPR/Cas9-edited, isogenic control (MAPT WT/WT-iso)
iPSCs.
(A) Diagram of reprogramming and CRISPR/Cas9 editing.
(B and C) Immunostaining (B) and qPCR (C) for pluripotency markers. Graph represents mean ± SEM.
(D) Sanger sequencing.
(E) Karyotyping.
(F and G) Spontaneous differentiation into cells within the three germ layers evaluated by RT-PCR (F) and immunostaining (G). MAPT
WT/WT (iPSC line: F11350); MAPT P301L/WT (iPSC line: F0510); MAPT WT-iso (iPSC line: F0510.2D20H1). Scale bars, 50 mm.
See also Table S1.2012). However, fibroblast lines fromMAPT P301S carriers,
which would be useful to validate mouse studies, were not
available for reprogramming at the time of this study. Thus,
we used CRISPR/Cas9 to mutate the MAPT P301L donor
iPSC line to MAPT P301S (Tables 4 and S2). For this series,
we performed whole-genome sequencing and analysis of
the mutational burden induced by genome editing and
observed no modifications at computationally predicted
off-target sites from CRISPR/Cas9 (Budde et al., 2017).
The mutational burden that was observed in the edited
iPSC lines was largely driven by selective pressures of cul-946 Stem Cell Reports j Vol. 13 j 939–955 j November 12, 2019ture (Bhutani et al., 2016; Budde et al., 2017; Merkle
et al., 2017).
To understand the specific contribution of MAPT muta-
tions and risk variants to disease phenotypes, we intro-
duced MAPT mutations into an unaffected control line.
In a control donor iPSC line (F11350) from a male individ-
ual carrying APOE 3/3 and MAPT H1/H1, we introduced
MAPT R5H, P301L, or G389R (Tables 4 and S2). In a second
control iPSC line (F13505) from a female individual car-
rying APOE 3/3 and MAPT H1/H1, we introduced MAPT
S305I or S305S (Tables 4 and S2). All resulting edited or
Table 4. CRISPR/Cas9-Edited iPSC Lines
Donor ID
Donor
Genotype
Isogenic
Genotype
Ngn2
Integration
Engineering
Methoda Line Name
Neural
Induction
F11362 R406W/WT WT/WT no CRISPR F11362.1D1C11, F11362.1D1B6 yes
F11421 R406W/WT WT/WT no CRISPR F11421.12D2A07 yes
F11374 R406W/WT N/A yes TALENs NF11374.65 yes
160311SBB1 V337M/WT WT/WT no CRISPR GIH6C1D1E11 yes
160311SBB2 V337M/WT WT/WT no CRISPR GIH7C2D2B12, GIH7C2D2F02 yes
ND32951A V337M/WT WT/WT no CRISPR ND32951A.15D1B06,
ND32951A.15D1C12
yes
GIH36 IVS10+16/WT WT/WT no CRISPR GIH36C2D1D01 yes
F0510 P301L/WT WT/WT no CRISPR F0510.2D2E7, F0510.2D20H1 yes
F0510 P301L/WT P301L/P301S no CRISPR F0510.2D3A11, F0510.2D3A9 yes
F0510 P301L/WT WT/P301S no CRISPR F0510.2D3E10, F0510.2D4B3,
F0510.2D4B4
yes
F0510 P301L/WT P301S/P301S no CRISPR F0510.2D3B5 yes
F0510 P301L/WT N/A yes TALENs NF0510.23, NF0510.12 yes
75.11 S305I/WT WT/WT no CRISPR 75.11-IW1A12 N/A
75.11 S305I/WT S305I/S305I no CRISPR 75.11-IH1B9 N/A
GP1.1 S305S/WT S305S/S305S no CRISPR GP1.1-SH1G8 N/A
F13505 WT/WT S305I/WT no CRISPR F13505.1-I1B10 N/A
F13505 WT/WT S305S/WT no CRISPR F13505.1-S3H5 N/A
F11350 WT/WT WT/R5H no CRISPR F11350.1.R5HD2F06 N/A
F11350 WT/WT WT/G389R no CRISPR F11350.1.G389R.1C05DE03 N/A
F11350 WT/WT P301L/P301L no CRISPR F11350.1.P301LD4A02,
F11350.1.P301LD4A08
N/A
F12468 WT/WT N/A yes TALENs NF12468.131 yes
WTC11 WT/WT N/A yes TALENs NWTC11.G3 yes
WTC11 WT/WT WT/WT yes TALENs/CRISPR NWTC11.G3.0036 yes
WTC11 WT/WT V337M/WT yes TALENs/CRISPR NWTC11.G3.0212 yes
WTC11 WT/WT V337M/V337M yes TALENs/CRISPR NWTC11.G3.3917 yes
aNgn2 was engineered by TALENs; MAPT mutations/corrections were engineered by CRISPR/Cas9.unmodified clones were characterized for pluripotency and
chromosomal stability as described above (Table S2). We
are continuing to build this collection on the same genetic
background with additional MAPT mutations.
Differentiation of iPSCs into Neural Progenitor Cells
and Differentiated Neural Cells
iPSCs have the capacity to form the diverse neural cell types
affected by primary tauopathies. By exploiting our under-standing of CNS development, several groups have estab-
lished protocols to generate neuroectodermal neural
progenitor cells (NPCs) that can be further patterned into
specific neuronal subtypes (Doi et al., 2014; Elkabetz
et al., 2008; Muratore et al., 2014). We adapted a neural
aggregate-based method that allows for the efficient gener-
ation of a scalable pool of NPCs, which have the capacity to
be patterned into cultures enriched for different types of
neurons or glia (Figure 3). Production of cryopreservedStem Cell Reports j Vol. 13 j 939–955 j November 12, 2019 947
Figure 3. Differentiation of iPSCs into Neural Progenitor Cells
(A) Diagram for neural progenitor derivation protocol.
(B–E) Bright-field images. (B) iPSC. (C) Neural aggregates. (D) Neural rosettes. (E) NPCs.
(F) RT-PCR of neural progenitor cell markers, NESTIN, SOX2, PAX6, and the housekeeping gene, ACTIN.
(G) Immunostaining for neural progenitor cell marker, PAX6.
(H and I) Immunostaining of iPSC-derived neurons. (H) Tuj1. (I) MAP2.
(J) Immunostaining of iPSC-derived astrocytes with GFAP.
Scale bars, 50 mm.banks of stable and expandable intermediate NPC popula-
tions will help to reduce time, effort, and variability across
experiments.
We have applied this neural induction protocol to the
donor lines in this collection across multiple laboratories
(Figure S1; Tables S1 and S2). We have verified that the
iPSC collection presented here has the capacity to form
NPCs that can be expanded and cryopreserved (Figures
3A–3E). These NPCs express early neuroectodermal
markers including PAX6, SOX2, and Nestin, and lack
expression of SOX10, which marks the neural crest, indi-
cating a CNS expression pattern (Figure 3F). The viability
of these NPCs after thaw is high (mean 89% ± 1.2% live
cells). These NPCs maintain their capacity to differentiate
into neuronal subtypes when used at early passages (be-
tween passage 1 and passage 5), while astrocyte differenti-
ation as measured by glial fibrillary acidic protein (GFAP)
and S100b can be promoted using NPCs from early or
later passages (beyond passage 5). By incorporating fluores-
cence-activated cell sorting for cell-surface markers
CD133+, CD184+, and CD271, the resulting selected
pool of NPCs can be maintained with a high proportion
of neuronal differentiation for at least 50 passages (Cheng
et al., 2017). It is critical to culture NPCs at a high density948 Stem Cell Reports j Vol. 13 j 939–955 j November 12, 2019for the successful maintenance of a stable and expandable
population of progenitors (Cheng et al., 2017).
NPCs can be patterned into different neural CNS regions
and differentiated into neuronal and glial subtypes to
model primary tauopathies (Figures 3I and 3J) (Jiang
et al., 2018; Silva et al., 2016; Tcw et al., 2017). By default,
these NPCs tend to adopt anterior CNS characteristics,
such as FOXG1 expression, but this fate can also be stimu-
lated by the addition of patterning factors (Kirwan et al.,
2015; Saurat et al., 2016). The resulting forebrain neurons
produce tau that is physiologically similar to human CNS
tau (Sato et al., 2018), with the exception of intracellular
4R tau levels. Achieving splicing of the six major tau iso-
forms expressed in adult brains remains a challenge in
the iPSC system (Hefti et al., 2018; Sposito et al., 2015).
Despite the low levels of 4R tau, iPSC-derived neural cells
from MAPT mutation/risk variant carriers phenocopy as-
pects of primary tauopathies. This includes the accumula-
tion of phosphorylated forms of tau (Ehrlich et al., 2015;
Imamura et al., 2016; Iovino et al., 2015; Silva et al.,
2016, 2019), mitochondrial defects (Esteras et al., 2017),
and increased cell vulnerability (Hallmann et al., 2017;
Silva et al., 2016; Wren et al., 2015). More recently, we
have demonstrated that neurons expressing MAPT
R406W (F11362) capture molecular signatures related to
altered synaptic function that are also present in human
brains from MAPT R406W carriers and in mouse models
of primary tauopathies (Jiang et al., 2018). Cryopreserved
NPCs from the iPSCs reported here (Tables 3 and 4) are
available upon request from http://neuralsci.org/tau.Generation of Integrated, Isogenic, and Inducible
Neurogenin-2 iPSCs
Integrated, isogenic, and inducible neurogenin-2 (i3N)
iPSCs engineered with a doxycycline-inducible mouse
Neurogenin-2 (Ngn2) transgene in the AAVS1 safe-harbor
locus can be scalably differentiated to homogeneous excit-
atory neurons, which enables the use of human neurons
for high-throughput drug discovery (Wang et al., 2017).
We have engineered two healthy control WT (F12468
and WTC11), as well as MAPT P301L (F0510) and MAPT
R406W (F11374), to i3N iPSCs (Table 4) (Wang et al.,
2017). We also mutagenized a control i3N line (WTC11)
to be heterozygous or homozygous for MAPT V337M
(Sohn et al., 2019). All modified lines were characterized
for chromosomal stability, and confirmed for Ngn2
integration and neuronal differentiation (Figure S2 and
Table S2), and are available upon request from http://
neuralsci.org/tau.DISCUSSION
We present a comprehensive and valuable resource that
can be used to model primary tauopathies and for drug
discovery. Our patient-based cohort consists of a library
of 140 dermal fibroblast lines and respective iPSC lines
with multiple clones that are focused on primary tauopa-
thies: 29 iPSC lines from patients carrying pathogenic
MAPT mutations or risk variants; 2 iPSC lines from au-
topsy-confirmed PSP patients; 28 isogenic iPSCs; and 8
Ngn2-integrated iPSCs. Importantly, most of these cell
lines were obtained from deeply clinically phenotyped
individuals with detailed neurological and neuropsycho-
logical assessment and availability of fluid biomarkers
(CSF and plasma), imaging biomarkers (MRI, b-amyloid
PET, and tau PET), genetic data, and, for some, neuropath-
ological data.Phenotypic Diversity of MAPT Mutations
More than 50 mutations in MAPT have been reported to
cause FTLD-Tau and are located primarily in exons 9–13;
yet FTLD-Tau is both clinically and neuropathologically
heterogeneous (Table 1). Broadly, FTLD-Tau is defined by
neuronal loss, gliosis, and spongiform changes in layer II
with predominant involvement of the frontal, temporal,
cingulate, and insular cortices and variable involvementof subcortical nuclei. Clinically, patients with FTLD-Tau
pathology can present with a broad range of phenotypes
spanning behavioral, cognitive, and motor disturbances.
Various different combinations of clinical symptoms may
be seen in association with specific mutations and even
among affected members of a single family (Spina et al.,
2008). Hence, there is a need to understand the impact of
specific MAPT mutations within the genetic background
of individuals with known clinical and pathological mani-
festations. Our fibroblast and iPSC resources allow for the
investigation of common and unique cellular phenotypes
driven by these mutations.
The Clinical and Pathological Spectrum of the Most
Common 4R Primary Tauopathies
FTLD-Tau, PSP, andCBD are neuropathologically defined as
4R tauopathies (Kovacs, 2015). PSP pathology occurs in
neurons and glia (astrocytes and oligodendrocytes) and
preferentially affects the tectum, tegmentum, globus pal-
lidus, diencephalon, and superior cerebellar peduncle
(Dickson et al., 2007). In CBD, neuronal and glial pathol-
ogy occurs within gray and white mater regions of the
cortex, basal ganglia, diencephalon, and rostral brainstem
(Forman et al., 2002). While 4R-tau aggregation is charac-
teristic of both PSP and CBD, differences in proteolytic
processing of tau have been reported to distinguish the
two diseases: detergent-insoluble tau occurs at a doublet
around 37 kDa in CBD and as a single band at 33 kDa in
PSP (Arai et al., 2001, 2004). The MAPT A152T risk variant
has been associated with both clinical and pathological
forms of PSP-S/PSP and CBS/CBD. Our fibroblast resources
containing sporadic PSP-S and CBS will allow for the
cellular and molecular dissection of disease phenotypes,
providing a powerful system for understanding the cellular
mechanisms that drive phenotypic differences between
PSP-S/PSP and CBS/CBD.
Challenges in Modeling Primary Tauopathies in
Traditional Cell and Mouse Models
Current cellular and animal models used to study primary
tauopathies have several limitations. Critically, there is no
natural animal model of tauopathy, as these diseases are
largely restricted toHomo sapiens (Heuer et al., 2012; Holzer
et al., 2004). While tau isoforms may share broad func-
tional similarities, different isoforms likely play distinct
physiological and pathological roles in the cell (Goedert
and Jakes, 1990; Karch et al., 2012; Kosik et al., 1989; Panda
et al., 2003). Notably, the expression of tau isoforms drasti-
cally differs between human and rodent brains. While the
adult human brains have roughly equal levels of 3R and 4R
tau, adult rodents express almost exclusively 4R tau,
limiting the conclusions that can be drawn from mouse
models (Trabzuni et al., 2012). Additionally, most cellularStem Cell Reports j Vol. 13 j 939–955 j November 12, 2019 949
and transgenic models (e.g., C. elegans, Drosophila, and
mice) rely on overexpression of a mutant transgene
comprising a single tau isoform, whichmay produce effects
that are a function of excessive protein expression, specific
isoform expression, and possible off-target effects, rather
than a disease-relevant phenotype. Finally, neuronal and
glial cells are the primary cell types affected in tauopathies;
therefore, studies in immortalized cell lines may fail to cap-
ture the phenotypes specific to neurons and glia. Thus, our
understanding of how tau is metabolized in the human
brain has been obtained from experimental paradigms
that do not fully capture physiological conditions relevant
to human tauopathies. Stem cell models begin to address
these gaps; however, tau generated by stem cell-derived
neurons remains in the fetal state (e.g., primarily 3R0N)
(Hefti et al., 2018; Iovino et al., 2015; Sposito et al.,
2015). Nevertheless, cells expressing 4R-containing MAPT
mutations, such as P301L, exhibit altered tau phosphoryla-
tion, tau accumulation, and cell vulnerability (Iovino et al.,
2015; Silva et al., 2019). These phenotypes can be reversed
with novel tau degraders (Silva et al., 2019).
Basic Science, Clinical, and Translational Applications
of Human Tauopathy Models
Beyond modeling the molecular and cellular pathophysi-
ology of primary tauopathies, the derivation of patient-
specific expandable NPCs enables large-scale functional
genomics, proteomics, and small-molecule-based and
CRISPR-based genetic modifier screens (Boselli et al.,
2017; Cheng et al., 2017; Silva et al., 2016; Tian et al.,
2019;Wang et al., 2017). This includes the use of high-con-
tent imaging methodologies with subcellular level resolu-
tion of molecular and morphological changes in defined
neuronal subtypes with and without glial subtypes. We
envision that using the framework of phenotypes from
the autosomal dominantmutations and risk factors for tau-
opathy described here will also assist in the interpretation
of genetic variants of unknown pathological significance
that are being identified by exome and whole-genome
sequencing projects.
One of the challenges inmodeling diseases that typically
present clinically in mid to late adulthood is to accelerate
aging in iPSC-derived cells. This is particularly difficult
given that during reprogramming to pluripotency, the
features of aging present in originating somatic cells are
reset. In contrast, fibroblasts directly reprogrammed into
neurons retain their aging characteristics such as DNA
methylation (Huh et al., 2016; Maherali et al., 2007; Mert-
ens et al., 2015). Efforts to induce chronological aging in
iPSC-derived neurons are under way (Miller et al., 2013).
In the meantime, the ability to study both reprogrammed
iPSCs and their source fibroblasts directly differentiated
into neurons may help the field dissect how gene muta-950 Stem Cell Reports j Vol. 13 j 939–955 j November 12, 2019tions contribute to the neurodegenerative process at both
early and late age-dependent stages.
Our intention is to extend the existing resource, particu-
larly by adding fibroblasts and iPSCs carrying novel muta-
tions with clear pathogenicity and unique clinical features
such as those associated with extremely early age of onset
or rapid disease progression. Other variants in specific
domains of tau or in non-coding genomic elements (e.g.,
50/30 UTRs, enhancer sites) would also be of interest to
the collection as well as additional genome engineering
in existing lines.Conclusions
In total, the resource presented here represents an opportu-
nity to understand the mechanisms by which pathogenic
mutations or risk variants in MAPT drive tauopathy. This
resource will also be of interest to the broader community
working on neurodegenerative disease. The collaborative
efforts through which this resource has been generated
can serve as a model for other neurodegenerative disease
subtypes as well as other neurological and non-neurolog-
ical diseases under genetic influence. Our intention is to
broadly share the collection of fibroblasts, iPSCs, and
NPCs and related data and information, which are avail-
able upon request. We are continuing to build this collec-
tion with additional reprogramming and genome editing,
and updates will be available at http://neuralsci.org/tau
(Figure S3).EXPERIMENTAL PROCEDURES
TheWashington University and University of California San Fran-
cisco Institutional Review Boards reviewed the Neuropathology
Cores (from whom the brains were obtained) operating protocols
as well as this specific study and determined it was exempt from
approval. Our participants provide this consent by signing the
hospital’s autopsy form. If the participant does not provide future
consent before death the DPOA or next of kin provide it after
death. All data were analyzed anonymously.
Skin punches were performed following written informed con-
sent from the donor. The informed consent was approved by the
Washington University School of Medicine and the University of
California San Francisco Institutional Review Board and Ethics
Committee (IRB 201104178, 201306108 and 10-03946). The
consent allows for use of tissue by all parties, commercial and
academic, for the purposes of research but not for use in human
therapy.
Peripheral blood mononuclear cells or dermal fibroblasts were
transduced with non-integrating Sendai virus carrying OCT3/4,
SOX2, KLF4, and cMYC. iPSC lines were analyzed for pluripotency
markers by immunocytochemistry (ICC) and qPCR; spontaneous
differentiation into the three germ layers by ICC or qPCR; and
chromosomal abnormalities by karyotyping. Human iPSCs were
edited using CRISPR/Cas9 as previously reported (Budde et al.,
2017). i3N iPSCs were generated as described previously (Wang
et al., 2017). See Supplemental Experimental Procedures for addi-
tional details.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2019.09.006.
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